G Medical Innovations Holdings Ltd. (ASX: GMV)
G Medical Innovations Holdings Ltd. (ASX: GMV) is a leading health care company is Australia. In the first half of FY 2018, the company reported a net loss of US$8.509 million against a loss of US$21.740 million in H1 FY 2017. The Company generated first half revenues of US$ 1.001 million which were mainly generated from G Medical Diagnostic Services. The revenues were offset by the operating expenses which increased from US$ 3.136 million in H1 2017 to US$ 9.067 million in H1 2018. The net cash used in operating activities increased from US$2.96 million in H1 2017 to US$9.10 million in H1 2018. The Net tangible asset backing per ordinary security changed from 0.035 cents in H1 2017 to 0.002 cents in H1 2018. Recently, the company announced that it has engaged a New York based Underwriter, to assist in the processes towards a US Public Offering through the NASDAQ Stock Exchange. The shares of GMV were in a trading halt; and as on 30 October 2018, the group announced about CE, FDA and CFDA Approval on its Guangzhou Production Facility. In the last three months, the share price of the company increased by 65.85 percent as on 26 October 2018. GMV’s shares last traded at $0.340 with a market capitalization of circa $121.3 million.
Bard 1 Life Science Ltd. (ASX: BD1)
BARD1 Life Sciences Limited (ASX: BD1) is a Perth based Biotech Company, which recently announced its world-first BARD1 Breast Cancer (BC) test for early detection of breast cancer, due to which in the five days the share price of the company increased by 150 percent as on 26 October 2018. However, the stock was down 11.11% on October 30, 2018 (3:30 PM AEST) post the stupendous rise. In FY 2018, the total comprehensive loss of the company decreased from $2.6 million in FY 2017 to $1.82 million in FY 2018. The basic and diluted loss per share of the company decreased from 0.45 cents in FY 2017 to 0.26 cents in FY 2018. The total current assets of the company increased from $0.699 million in FY 2017 to $1.45 million in FY 2018. The cash flow used in operating activities decreased from $2.38 million in FY 2017 to $1.96 million in FY 2018. BARD1 is exploring a range of funding and corporate options and opportunities, with a guiding principle of minimizing dilution and driving value for all shareholders. BD1’s shares traded at $0.048 with a market capitalization of $44.75 million as on 30 October 2018 (AEST 3:30 PM).
Suda Pharmaceuticals Ltd. (ASX: SUD)
Suda Pharmaceuticals Ltd. (ASX: SUD) is involved in the operations of commercialization and development of pharmaceutical products through new methods of delivery. In the recently released market update of September quarter, the company announced that it has raised a gross amount of $6,120,709 through a renounceable rights issue and, as the rights issue was heavily oversubscribed, the Company raised a further $668,376 via an additional placement. Following this release, the share price of the company witnessed an intra-day decrease of 28.571 percent as on 29 October 2018. During the September quarter, the Company has expanded its Scientific Advisory Board with the appointment of Professor Stephen Watson. SUDA’s scientists have managed to increase the solubility of anagrelide by a factor of 60-fold allowing SUDA to achieve potentially therapeutic doses with its OroMist® spray technology. The company has seen an increasing number of new incoming contacts over the past 3 months for existing projects as well as new opportunities. The management team are working on various discussions that are at different stages of completion with potential partners for codevelopment of new projects. The Net cash from / (used in) operating activities in the September quarter is $1.86 million. SUD’s shares traded at $0.005 with a market capitalization of $12.9 million as on 30 October 2018.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.